<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02693717</url>
  </required_header>
  <id_info>
    <org_study_id>2015-0592</org_study_id>
    <secondary_id>NCI-2016-00390</secondary_id>
    <secondary_id>2015-0592</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT02693717</nct_id>
  </id_info>
  <brief_title>Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer</brief_title>
  <official_title>A Phase II Trial to Evaluate Pemetrexed Clinical Responses in Relation to Tumor MTAP Gene Status in Patients With Previously Treated Metastatic Urothelial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well pemetrexed disodium works in treating patients with&#xD;
      previously treated urothelial cancer that has spread from the primary site (place where it&#xD;
      started) to other places in the body. Pemetrexed disodium may stop the growth of tumor cells&#xD;
      by blocking some of the enzymes needed for cell growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      To determine the objective response rates (ORR) to pemetrexed disodium (pemetrexed) in&#xD;
      patients with MTAP-deficient metastatic bladder cancer.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the progression-free survival (PFS) for patients with MTAP-deficient&#xD;
      metastatic bladder cancer treated with pemetrexed.&#xD;
&#xD;
      II. To determine the overall survival (OS) for patients with MTAP-deficient metastatic&#xD;
      bladder cancer treated with pemetrexed.&#xD;
&#xD;
      III. Evaluate the toxicity of pemetrexed therapy for patients with MTAP-deficient metastatic&#xD;
      bladder cancer.&#xD;
&#xD;
      IV. Collect blood, urine, and tissue for future translational studies.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive pemetrexed disodium intravenously (IV) over 10 minutes on day 1. Courses&#xD;
      repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 3 weeks and then every 3&#xD;
      months for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The trial was closed due to the changing efficacy of treatments for metastatic urothelial&#xD;
    cancer.&#xD;
  </why_stopped>
  <start_date type="Actual">May 9, 2017</start_date>
  <completion_date type="Actual">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">December 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rates</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be defined as the number of subjects with complete response or partial response by Response Assessment in Solid Tumors 1.1 criteria divided by the total number of subjects receiving their first dose of trial therapy. Objective response rates will be summarized using descriptive statistics.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Time from trial entry to the first documented tumor progression as determined by the investigator using the Response Evaluation Criteria in Solid Tumors 1.1 criteria or death from any cause, assessed at 2 years</time_frame>
    <description>Progression-free survival will be estimated and plotted with the methods of Kaplan and Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Time from trial entry to death from any cause, assessed at 2 years</time_frame>
    <description>Overall survival will be estimated and plotted with the methods of Kaplan and Meier.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Metastatic Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (pemetrexed disodium)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (pemetrexed disodium)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed Disodium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (pemetrexed disodium)</arm_group_label>
    <other_name>Alimta</other_name>
    <other_name>LY231514</other_name>
    <other_name>N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidine-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histological confirmation of metastatic urothelial carcinoma;&#xD;
             patients must have sufficient tumor tissues for future MTAP testing and research;&#xD;
             histological variants such as glandular, squamous, sarcomatoid, micropapillary,&#xD;
             plasmacytoid, and small cell changes will not be allowed for this trial unless these&#xD;
             tumors are MTAP-deficient&#xD;
&#xD;
          -  All patients must have measurable disease and tumors of sufficient sizes for biopsy;&#xD;
             in general, liver and lung lesions should be at least 1.0 cm, and patients with lymph&#xD;
             node-only disease should have lesions of &gt;= 1.5 cm in shortest dimension; patients&#xD;
             with disease confined to bone may be eligible if a measurable lytic defect is present;&#xD;
             the study principal investigator (PI) is the final arbiter in questions related to&#xD;
             measurability; patients with a three-dimensional mass or pelvic sidewall fixation on&#xD;
             bladder examination under anesthesia are considered to have measurable disease&#xD;
&#xD;
          -  Patients who have received any non-anti-folate containing neoadjuvant or systemic&#xD;
             chemotherapy are eligible; any prior intravesical therapy, or immunotherapy is allowed&#xD;
&#xD;
          -  Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status =&lt;&#xD;
             2&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =&lt; 3 x upper limit&#xD;
             normal (ULN), or =&lt; 5 x ULN if documented liver metastases are present&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x ULN, except subjects with Gilbert's syndrome or liver&#xD;
             metastases, who must have a baseline total bilirubin =&lt; 3.0 mg/dL&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1500&#xD;
&#xD;
          -  Platelets &gt;= 100,000&#xD;
&#xD;
          -  Normal serum creatinine, or a creatinine clearance &gt;= 40 ml/min (either measured using&#xD;
             a 24 hour urine, calculated using Cockroft-Gault, or estimated using the Modification&#xD;
             of Diet in Renal Disease [MDRD] method from the National Kidney Disease Education&#xD;
             Program [NKDEP] [the method reported by M D Anderson Cancer Center (MDACC)&#xD;
             laboratories])&#xD;
&#xD;
          -  Females of childbearing potential who are sexually active with a non-sterilized male&#xD;
             partner and non-sterilized males must use a highly effective method of contraception&#xD;
             for 28 days prior to the first dose of investigational product, and must agree to&#xD;
             continue using such precautions for 180 days after the final dose of investigational&#xD;
             product; cessation of contraception after this point should be discussed with a&#xD;
             responsible physician&#xD;
&#xD;
          -  Females of childbearing potential must also refrain from egg cell donation for 180&#xD;
             days after the final dose of investigational product;&#xD;
&#xD;
               -  Females of childbearing potential are defined as those who are not surgically&#xD;
                  sterile (ie, bilateral tubal ligation, bilateral oophorectomy, or complete&#xD;
                  hysterectomy) or postmenopausal (defined as 12 months with no menses without an&#xD;
                  alternative medical cause)&#xD;
&#xD;
               -  A highly effective method of contraception is defined as one that results in a&#xD;
                  low failure rate (ie, less than 1% per year) when used consistently and&#xD;
                  correctly; the acceptable methods of contraception are: barrier method (e.g. male&#xD;
                  condom with spermicide, copper T intrauterine device, or levonorgestrel-releasing&#xD;
                  intrauterine system - Mirena) or hormonal methods (e.g. implants, hormone shot or&#xD;
                  injection, combined pill, minipill, or patch); non-sterilized males who are&#xD;
                  sexually active with a female partner of childbearing potential must use a highly&#xD;
                  effective method of contraception from days 1-180 post last dose; in addition,&#xD;
                  they must refrain from sperm donation for 180 days after the final dose of&#xD;
                  investigational product&#xD;
&#xD;
          -  The ability to interrupt nonsteroidal antiinflammatory drug (NSAIDS) 2 days before (5&#xD;
             days for long-acting NSAIDs), the day of, and 2 days following administration of&#xD;
             pemetrexed&#xD;
&#xD;
          -  The ability to take folic acid, vitamin B12, and dexamethasone according to protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary central nervous system (CNS) malignancies or CNS metastases, including&#xD;
             leptomeningeal metastases, are not allowed; subjects with previously treated brain&#xD;
             metastases will be allowed if the brain metastases have been stable for at least 3&#xD;
             months following prior treatment (radiotherapy or surgery)&#xD;
&#xD;
          -  Patients who received previous anti-folate-containing chemotherapy&#xD;
&#xD;
          -  Any other malignancy from which the patient has been disease-free for less than 3&#xD;
             years, except for non-melanoma skin cancer, controlled localized prostate cancer, in&#xD;
             situ carcinoma of any site&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
&#xD;
          -  Presence of third space fluid which cannot be controlled by drainage; for patients who&#xD;
             develop or have baseline clinically significant pleural or peritoneal effusions (on&#xD;
             the basis of symptoms or clinical examination) before or during initiation of&#xD;
             pemetrexed therapy, consideration should be given to draining the effusion prior to&#xD;
             dosing; however, if, in the investigator's opinion, the effusion represents&#xD;
             progression of disease, the patient should be discontinued from study therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianjun Gao</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 18, 2016</study_first_submitted>
  <study_first_submitted_qc>February 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2016</study_first_posted>
  <results_first_submitted>March 31, 2021</results_first_submitted>
  <results_first_submitted_qc>May 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 20, 2021</results_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 29, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT02693717/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The participants were accrued starting in Sept 2017 through January 2019.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Pemetrexed</title>
          <description>Intravenous infusion 500 mg/m2 every 21 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pemetrexed</title>
          <description>Intravenous infusion 500 mg/m2 every 21 days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.6" lower_limit="68" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rates</title>
        <description>Will be defined as the number of subjects with complete response or partial response by Response Assessment in Solid Tumors 1.1 criteria divided by the total number of subjects receiving their first dose of trial therapy. Objective response rates will be summarized using descriptive statistics.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Study terminated early, no data collected</population>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed</title>
            <description>Intravenous infusion 500 mg/m2 every 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rates</title>
          <description>Will be defined as the number of subjects with complete response or partial response by Response Assessment in Solid Tumors 1.1 criteria divided by the total number of subjects receiving their first dose of trial therapy. Objective response rates will be summarized using descriptive statistics.</description>
          <population>Study terminated early, no data collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>Progression-free survival will be estimated and plotted with the methods of Kaplan and Meier.</description>
        <time_frame>Time from trial entry to the first documented tumor progression as determined by the investigator using the Response Evaluation Criteria in Solid Tumors 1.1 criteria or death from any cause, assessed at 2 years</time_frame>
        <population>Study terminated early, no data collected</population>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed</title>
            <description>Intravenous infusion 500 mg/m2 every 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Progression-free survival will be estimated and plotted with the methods of Kaplan and Meier.</description>
          <population>Study terminated early, no data collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival will be estimated and plotted with the methods of Kaplan and Meier.</description>
        <time_frame>Time from trial entry to death from any cause, assessed at 2 years</time_frame>
        <population>Study terminated early, no data collected</population>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed</title>
            <description>Intravenous infusion 500 mg/m2 every 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival will be estimated and plotted with the methods of Kaplan and Meier.</description>
          <population>Study terminated early, no data collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <desc>Study terminated early, no data collected</desc>
      <group_list>
        <group group_id="E1">
          <title>Pemetrexed</title>
          <description>Intravenous infusion 500 mg/m2 every 21 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This protocol was stopped early as it was considered unethical. A new protocol with the same study drugs plus an immune check point drug was added. There is no data to report.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jianjun Gao, MD PHD, Associate Professor, Genitourinary Medical Oncology</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>(713) 563-4195</phone>
      <email>jgao1@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

